High tide to become major player in german medical cannabis market through acquisition of majority stake in remexian pharma gmbh

Remexian generated €65 million in revenue in the last 12 months remexian sold 7 tonnes of cannabis flower in q2 2025, representing 16% of the 43 tonnes imported into germany in the quarter1 calgary, ab , aug. 14, 2025 /prnewswire/ - high tide inc. ("high tide" or the "company") (nasdaq: hiti) (tsxv: hiti) (fse: 2lya), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that it is entering the fast growing german medical cannabis market by signing a definitive agreement (the "acquisition agreement") pursuant to which the company will acquire 51% of remexian pharma gmbh ("remexian"), for a preliminary estimated purchase price of €27.2 million, subject to certain adjustments on closing (the "transaction"), and will have an option to acquire the remaining interest in remexian. founded in 2018 and headquartered just outside of berlin, germany, remexian is a leading and established pharmaceutical company built for the purpose of importation and wholesale of medical cannabis, and has a fully certified eu gdp warehouse.
HITI Ratings Summary
HITI Quant Ranking